22:56 , Aug 9, 2018 |  BC Extra  |  Preclinical News

New biological insight could lead to obesity treatment

By identifying a mechanism in dietary fat uptake, researchers from Yale University School of Medicine suggest a compound marketed for glaucoma could have therapeutic applications in obesity. The study was published Thursday in Science. Dietary fats...
20:30 , Dec 5, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Brain cancer Mouse studies suggest inhibiting NRP1 in microglia and peripheral macrophages could help treat glioma. In a bone marrow-ablated mouse model of glioma, bone marrow transplants engineered to produce NRP1-knockout macrophages decreased tumor volume...
20:05 , Jan 12, 2017 |  BC Innovations  |  Emerging Company Profile

Looking beyond VEGF

SemaThera Inc. launched this week to develop a recombinant SEMA3A trap to treat vascular pathologies in the large fraction of diabetic macular edema (DME) patients who don’t respond to marketed anti-VEGF therapies. Semaphorins are a family...
08:00 , Nov 12, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Vascular endothelial growth factor receptor 1 (FLT1; VEGFR-1); neuropilin 1 (NRP1)

Ophthalmic disease Animal studies suggest local delivery of a small cyclic peptidomimetic inhibitor of FLT1 and NRP1 could help treat AMD and retinopathy of prematurity (ROP). In a monkey model of AMD, an eye drop formulation...
07:00 , Mar 30, 2015 |  BC Week In Review  |  Clinical News

Tivozanib: Phase II final data

An analysis of patients with low serum neuropilin 1 (NRP1) levels in the open-label, international Phase II BATON-CRC trial in 265 patients with previously untreated mCRC showed that first-line treatment with tivozanib plus mFOLFOX6...
07:00 , Jul 17, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Ophthalmic disease v-abl Abelson murine leukemia viral oncogene homolog 1 (ABL1); neuropilin 1 (NRP1) In vitro...
08:00 , Nov 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Ophthalmic disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Ophthalmic disease Diabetic retinopathy Semaphorin 3A (SEMA3A); neuropilin 1 (NRP1) Mouse studies suggest inhibiting SEMA3A could help treat...
07:00 , Aug 22, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Neuropilin 1 (NRP1); semaphorin 4A (SEMA4A) Mouse studies suggest blocking SEMA4A-NRP1...
07:00 , Aug 22, 2013 |  BC Innovations  |  Targets & Mechanisms

Subverting Treg-mediated protection for tumors

Treg cells present a conundrum for cancer researchers-although these cells can suppress the antitumor immune response, depleting them can trigger severe inflammation and autoimmunity. Now, a team of researchers at St. Jude Children's Research Hospital...
07:00 , Mar 14, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer Placental growth factor (PGF; PlGF); neuropilin 1 (NRP1) In vitro and mouse studies suggest...